Featured Article

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Blog
ICH E6(R3), Demystified Part 4: Informed Consent
  • From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...
Read More
Blog
Why RBQM Programs Stall: The Gap Between Insight and Action
  • Many organizations invest heavily in detection, analytics, dashboards, and centralized monitoring. Yet RBQM still stalls. The...
Read More
Blog
RBQM for the Mid-Market Explained
  • Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI